Fortrea Holdings Inc. (FTRE)
NASDAQ: FTRE · Real-Time Price · USD
18.45
+0.73 (4.12%)
Sep 2, 2026, 10:54 AM EDT - Market open
Fortrea Holdings Revenue
Fortrea Holdings had revenue of $678.20M in the quarter ending June 30, 2026, a decrease of -4.52%. This brings the company's revenue in the last twelve months to $2.68B, down -2.09% year-over-year. In the year 2025, Fortrea Holdings had annual revenue of $2.72B with 1.00% growth.
Revenue (ttm)
$2.68B
Revenue Growth
-2.09%
P/S Ratio
0.63
Revenue / Employee
$191,179
Employees
14,000
Market Cap
1.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.72B | 27.00M | 1.00% |
| Dec 31, 2024 | 2.70B | -27.00M | -0.99% |
| Dec 31, 2023 | 2.72B | 27.00M | 1.00% |
| Dec 31, 2022 | 2.70B | -146.10M | -5.14% |
| Dec 31, 2021 | 2.84B | 262.20M | 10.16% |
| Dec 31, 2020 | 2.58B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immunocore Holdings | 430.78M |
| Vir Biotechnology | 303.23M |
| Syndax Pharmaceuticals | 252.25M |
| Septerna | 98.88M |
| Intellia Therapeutics | 59.51M |
| Recursion Pharmaceuticals | 54.86M |
| Taysha Gene Therapies | 5.49M |
| Inhibrx Biosciences | 1.30M |
FTRE News
- 3 hours ago - Fortrea to buy Worldwide Clinical Trials Early Phase Services division for $45M - TheFly
- 4 hours ago - Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - GlobeNewsWire
- 4 weeks ago - Fortrea price target raised to $23 from $19 at TD Cowen - TheFly
- 4 weeks ago - Fortrea price target raised to $22 from $20 at Citi - TheFly
- 4 weeks ago - Fortrea price target raised to $20 from $18 at Deutsche Bank - TheFly
- 4 weeks ago - Fortrea price target raised to $23 from $21 at Baird - TheFly
- 4 weeks ago - Fortrea price target raised to $22 from $18 at Barclays - TheFly
- 4 weeks ago - Fortrea price target raised to $25 from $20 at Evercore ISI - TheFly